CDKN2A and pancreatic neoplasm: These guidelines suggest that candidacy for counseling and CDKN2A testing be based on the number of (1) invasive primary melanomas in the identified patient (proband), (2) invasive melanomas in blood relatives, and (3) the numbers of pancreatic cancers in the proband or blood relatives.